"Switch between originator infliximab (Remicade) and biosimilar infliximab (Remsima) in the treatment of rheumatoid arthritis, spondyloarthritis and chronic inflammatory bowel diseases. Evaluation of immunogenicity and clinical response"
Phase of Trial: Phase IV
Latest Information Update: 18 Dec 2018
Price : $35 *
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis
- Focus Adverse reactions
- Acronyms Re-IMPROVE
- 12 Dec 2018 Status changed from recruiting to discontinued.
- 23 Nov 2018 New trial record